Myasthenia Gravis Therapeutics Market Size to Reach USD 3.48 Billion by 2033 Driven by Advancements in Targeted Biologic Therapies

According to DataM Intelligence, the global myasthenia gravis therapeutics market was valued at USD 1.64 billion in 2025 and is projected to reach USD 3.48 billion by 2033, growing at a CAGR of 9.6% during the forecast period (2026-2033).
The market is witnessing steady growth due to the rising prevalence of autoimmune disorders, increasing awareness of early diagnosis, and growing adoption of targeted therapies for rare neurological diseases. Myasthenia gravis requires lifelong disease management, driving demand for advanced treatment options including monoclonal antibodies, FcRn inhibitors, complement inhibitors, immunosuppressants, and cholinesterase inhibitors. Increasing investments in rare disease research, favorable orphan drug policies, and continuous innovation in biologic therapies are further supporting market expansion. Additionally, improving healthcare infrastructure and expanding access to specialized neurological care are expected to create long-term growth opportunities for market participants.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for Quick Response): https://www.datamintelligence.com/download-sample/myasthenia-gravis-therapeutics-market?indhu

Recent Developments
• 2026: argenx expanded the clinical reach of VYVGART and VYVGART Hytrulo following the U.S. FDA label expansion, enabling treatment for all adult patients with generalized myasthenia gravis regardless of antibody subtype.
• 2026: Johnson & Johnson strengthened its global myasthenia gravis portfolio after securing regulatory approval in China for nipocalimab (IMAAVY) to treat generalized myasthenia gravis in patients aged 12 years and older.
• 2026: Cartesian Therapeutics advanced the development of Descartes-08 by progressing its Phase III AURORA trial, supporting commercialization efforts for its mRNA-based cell therapy in generalized myasthenia gravis.
• 2026: Kyverna Therapeutics accelerated the clinical development of KYV-101 by initiating its registrational Phase III trial in generalized myasthenia gravis, marking continued progress in CAR-T therapies for autoimmune diseases.

Mergers & Acquisitions
• July 2026: Kyverna Therapeutics entered a commercial manufacturing and supply agreement with ElevateBio to support large-scale production of miv-cel for generalized myasthenia gravis (gMG). The partnership strengthens manufacturing readiness ahead of potential commercialization and global clinical expansion.
• June 2026: Cartesian Therapeutics signed a strategic licensing agreement with WestGene Biopharma to accelerate the development of its in vivo CAR-T platform for autoimmune diseases, including myasthenia gravis. The collaboration combines WestGene's lipid nanoparticle technology with Cartesian's mRNA platform to advance next-generation therapies.

Myasthenia Gravis Therapeutics Market Segmentation
• By Drug Class
o Cholinesterase Inhibitors
o Corticosteroids
o Immunosuppressants
o Monoclonal Antibodies
o Intravenous Immunoglobulin (IVIg)
o Others
• By Route of Administration
o Oral
o Injectable
• By Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• By Region
o North America
o Europe
o Asia-Pacific
o South America
o Middle East & Africa

Competitive Landscape
The myasthenia gravis therapeutics market is moderately competitive, with leading pharmaceutical companies focusing on biologics, rare disease drug development, strategic collaborations, product approvals, and pipeline expansion to strengthen their market presence.
Key Players
• Alexion Pharmaceuticals Inc.
• Novartis AG
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Grifols S.A.

Speak to Our Analyst and Get Customization in the Report as per Your Requirements: https://www.datamintelligence.com/customize/myasthenia-gravis-therapeutics-market?indhu

Regional Analysis
North America dominates the global myasthenia gravis therapeutics market owing to strong healthcare infrastructure, increasing rare disease awareness, favorable orphan drug regulations, and significant investments in biologic drug development. The presence of major pharmaceutical companies and growing regulatory support continue to drive regional market growth.
Asia-Pacific is expected to witness the fastest growth during the forecast period due to improving diagnostic capabilities, increasing healthcare expenditure, expanding access to biologic therapies, and rising awareness of autoimmune neurological disorders. Countries such as Japan, China, and India are investing in advanced healthcare infrastructure, supporting greater adoption of innovative treatment options.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=myasthenia-gravis-therapeutics-market?indhu

Conclusion
The myasthenia gravis therapeutics market forecast remains highly promising as continuous advancements in biologic therapies, FcRn inhibitors, complement inhibitors, and precision medicine transform the treatment landscape for autoimmune neurological disorders. Growing investments in rare disease research, expanding orphan drug incentives, and increasing awareness of early diagnosis are expected to accelerate market growth over the coming years.
As pharmaceutical companies continue to expand their biologics pipelines and develop innovative targeted therapies, the myasthenia gravis therapeutics industry is expected to offer substantial opportunities for manufacturers, healthcare providers, researchers, and investors while improving long-term outcomes for patients worldwide.

Industry Related Reports

Capsid Inhibitor Market Size
The global Capsid Inhibitor Market is modeled at US$ 1.42 billion in 2025 and is projected to reach US$ 7.86 billion by 2035, expanding at a CAGR of 18.7% during 2026-2035. Growth is driven by the emergence of capsid inhibition as a clinically validated antiviral mechanism, the expansion of long-acting HIV treatment and prevention, and continued development of HBV capsid assembly modulators.
Give more insights: https://www.datamintelligence.com/research-report/capsid-inhibitor-market?indhu

Ataxia Market Share
The global Ataxia Market reached an estimated US$ 2.38 billion in 2025 and is expected to reach US$ 6.71 billion by 2035, growing at a CAGR of 10.9% during the forecast period 2026-2035. Market growth is supported by increasing adoption of disease-modifying therapies, advances in genetic diagnostics, expanding rare disease research, and improved multidisciplinary care for hereditary and acquired ataxias.
Give more insights: https://www.datamintelligence.com/research-report/ataxia-market?indhu

Explore more Japan Reports: https://www.datamintelligence.com/jp-market-research-report?indhu

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About Us :
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.